Concepedia

J.C-H. Yang

JY

Statistics

Publications

8

Citations

268

H-Index

8

Active since

2015

Affiliations

National Cancer Center Hospital East(Current)

Sungkyunkwan University

Samsung Medical Center

National Taiwan University

Dana-Farber Cancer Institute

J.C-H. Yang is an author at National Cancer Center Hospital East specializing in oncology, medicine, and molecular oncology.

ORCID

Publications per year

2015–2023

8

Publications

8

LBA1_PR: Osimertinib as first-line treatment for EGFR mutation-positive advanced NSCLC: updated efficacy and safety results from two Phase I expansion cohorts

Suresh S. Ramalingam, J.C-H. Yang, Chee Khoon Lee et al. · Journal of Thoracic Oncology · 2016 · 68 citations · Full text

, , +10

LBA55 Trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-mutant metastatic non-small cell lung cancer (NSCLC): Interim results from the phase 2 DESTINY-Lung02 trial

Keiko Goto, K. Sang-We, Takafumi Kubo et al. · Annals of Oncology · 2022 · 60 citations · Full text

, , +17

3083 AZD9291 activity in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC) and brain metastases: Data from Phase II studies

M.-J. Ahn, C.M. Tsai, J.C-H. Yang et al. · European Journal of Cancer · 2015 · 42 citations

, , +17

OA04.04 Amivantamab in Post-platinum EGFR Exon 20 Insertion Mutant Non-small Cell Lung Cancer

Joshua K. Sabari, Catherine A. Shu, K. Park et al. · Journal of Thoracic Oncology · 2021 · 40 citations · Full text

, , +16

Overall survival (OS) in patients (pts) with EGFR T790M-positive advanced non-small cell lung cancer (NSCLC) treated with osimertinib: Results from two phase II studies

Tetsuya Mitsudomi, M-J. Ahn, Lyudmila Bazhenova et al. · Annals of Oncology · 2017 · 17 citations

, , +17

1–5 of 8